What's New 

Latest Editorial Releases

Sublingual Epinephrine for Anaphylaxis Receives Fast Track Designation from FDA

WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AQST-109, the first and only orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis.


Read More

Asia-Pacific perspectives on the COVID-19 pandemic

Coronavirus disease 2019 (COVID-19) has affected over ten millions of people globally since the World Health Organization declared it a pandemic on 11 March 2020. The Asia-Pacific is a diverse geographical region with different health care systems and levels of access to specialist services. This survey was commissioned by the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI) Task Force on COVID-19 with the premise to understand the epidemiology, clinical profile (including severity and risk factors), therapeutics/access to clinical trials, impact on clinical immunology and allergy services/therapeutics, occupational health and mental well-being (supporting information S1, S2) of healthcare providers in the region.


Read More

Women in Science and Medicine

Science and medicine know no barriers, no country, no language. They are universal tools for the benefit of humankind meant to be accessible to everyone, both men and women. As women physician scientists, we all have had our own journeys wanting to be part of science and medicine.


Read More